Invizius Receives Major Biomedical Catalyst Grant to Bring Anti-Inflammatory Hemodialysis Treatment to Clinic

£1million grant will support H-Guard’s first-in-human clinical trials

GLASGOW, Scotland, March 30, 2022 /PRNewswire/ — Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H -Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of hemodialysis, in the clinic. The funds will be used for H-Guard’s First-in-Man security study beginning in 2022.

There are currently 3.3 million hemodialysis patients worldwide who receive treatment several times a week. Dialysis treatment can reduce life expectancy by two-thirds, and nearly half of patients die of cardiovascular complications, partly caused by the immune system’s reaction to dialysis machine components.

H-Guard® Priming Solution includes a new protein that lines the inside of the dialysis filter and helps dialysis proceed undetected by the body’s immune system. This suppresses the foreign body response from the blood, preventing a repetitive and hostile inflammatory reaction that increases the risk of cardiovascular complications.

Richard BoydCEO of Invizius, said: “We are delighted to have received this grant from the Biomedical Catalyst to bring our potentially life-saving treatment to the clinic to improve outcomes and quality of life for hemodialysis patients. To be one of 17 winners selected from 302 applicants is an honor and validates the potential of our cutting-edge technology to address a huge unmet need for patients on hemodialysis.We are initially targeting patients with a high innate immune response to dialysis, where the global market for H-Guard is estimated at over £1.5 billion.”

Invizius is backed by a strong syndicate of investors including Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures, Calculus Capital and experienced life science entrepreneur and investor, Dr jonathan milner. The Company established the regulatory pathway for H-Guard® by North America and the possibility of a coincident approval in Europe.

About Invizius

Invizius Limited is a late-stage preclinical biotechnology company developing treatments to suppress unwanted innate immune responses, initially focused on reducing the life-threatening inflammatory effects of dialysis. Founded in 2017, the Edinburgh University spin-out is developing its exclusive H-Guard® priming solution, featuring a new protein that lines the inside of the dialysis filter and helps dialysis proceed undetected by the body’s immune system. This suppresses the foreign body response from the blood, thus preventing a hostile inflammatory reaction. The technology can also be used with other devices or treatments such as continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass, organ transplants and immunomodulatory therapies. The company is looking to expand its product portfolio to other high-value indications.

For more information about Invizius, visit: www.invizius.com

About Biomedical Catalyst

The Biomedical Catalyst (BMC) is a unique partnership between the MRC and Innovate UK, providing responsive and efficient support for the most innovative life science opportunities, regardless of scientific approach. The BMC aims to de-risk innovative science and commercialize ideas from academia and industry by helping UK SMEs develop into competitive and sustainable organisations. This speeds up bringing new products to market, facilitates subsequent investments and bridges the “valley of death”. For more information, please visit: https://mrc.ukri.org/funding/science-areas/translation/biomedical-catalyst/

Innovate in the UK

Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a UK government grant. Innovate UK drives productivity and economic growth by helping businesses develop and realize the potential of new ideas, including those from the UK’s world-class research base. They connect companies to partners, customers and investors who can help turn those ideas into commercially successful products and services, and business growth. For more information, please visit www.innovateuk.org.

SOURCEInvizius

Comments are closed.